Consolidated statement of income
€ in millions |
|
|
2024 |
|
2023 |
|
2023 previous |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue |
|
4 |
|
21,833 |
|
21,067 |
|
22,299 |
||||||
Costs of revenue |
|
|
|
-16,455 |
|
-16,096 |
|
-17,241 |
||||||
Gross profit |
|
|
|
5,378 |
|
4,971 |
|
5,058 |
||||||
Selling expenses |
|
|
|
-697 |
|
-742 |
|
-750 |
||||||
General and administrative expenses |
|
8 |
|
-2,222 |
|
-2,285 |
|
-2,405 |
||||||
Other operating income |
|
9 |
|
293 |
|
417 |
|
402 |
||||||
Other operating expenses |
|
9 |
|
-329 |
|
-517 |
|
-501 |
||||||
Research and development expenses |
|
7 |
|
-641 |
|
-661 |
|
-661 |
||||||
Operating income (EBIT) |
|
|
|
1,782 |
|
1,183 |
|
1,143 |
||||||
Income from investments accounted for using the equity method |
|
22 |
|
38 |
|
-12 |
|
-12 |
||||||
Interest income |
|
10 |
|
115 |
|
121 |
|
118 |
||||||
Interest expenses |
|
10 |
|
-547 |
|
-519 |
|
-534 |
||||||
Income before income taxes |
|
|
|
1,388 |
|
773 |
|
715 |
||||||
Income taxes |
|
11 |
|
-521 |
|
-485 |
|
-477 |
||||||
Net income from continuing operations |
|
|
|
867 |
|
288 |
|
238 |
||||||
Noncontrolling interests in continuing operations |
|
12 |
|
-34 |
|
-110 |
|
-115 |
||||||
Net income from continuing operations attributable to shareholders of Fresenius SE & Co. KGaA |
|
|
|
901 |
|
398 |
|
353 |
||||||
|
|
|
|
|
|
|
|
|
||||||
Net income from deconsolidated Fresenius Medical Care operations under IFRS 5 |
|
|
|
n.a. |
|
-1,938 |
|
-1,938 |
||||||
Noncontrolling interests in deconsolidated Fresenius Medical Care operations under IFRS 5 |
|
|
|
n.a. |
|
-991 |
|
-991 |
||||||
Net income from deconsolidated Fresenius Medical Care operations under IFRS 5 attributable to shareholders of Fresenius SE & Co. KGaA |
|
|
|
n.a. |
|
-947 |
|
-947 |
||||||
|
|
|
|
|
|
|
|
|
||||||
Net income from discontinued operations |
|
|
|
-571 |
|
-50 |
|
n.a. |
||||||
Noncontrolling interests from discontinued operations |
|
|
|
-141 |
|
-5 |
|
n.a. |
||||||
Net income from discontinued operations attributable to shareholders of Fresenius SE & Co. KGaA |
|
|
|
-430 |
|
-45 |
|
n.a. |
||||||
|
|
|
|
|
|
|
|
|
||||||
Net income |
|
|
|
296 |
|
-1,700 |
|
-1,700 |
||||||
Noncontrolling interests in net income |
|
|
|
-175 |
|
-1,106 |
|
-1,106 |
||||||
Net income attributable to shareholders of |
|
|
|
471 |
|
-594 |
|
-594 |
||||||
|
|
|
|
|
|
|
|
|
||||||
Earnings per share in € (basic and diluted) |
|
14 |
|
0.84 |
|
-1.05 |
|
-1.05 |
||||||
thereof based on net income from continuing operations |
|
|
|
1.60 |
|
0.71 |
|
0.63 |
||||||
thereof based on net income from deconsolidated Fresenius Medical Care operations under IFRS 5 |
|
|
|
n.a. |
|
-1.68 |
|
-1.68 |
||||||
thereof based on net income from discontinued operations |
|
|
|
-0.76 |
|
-0.08 |
|
n.a. |
||||||
|
||||||||||||||